Short Answer

Both the model and the market expect the FDA to reclassify BPC-157 to Category 1 before 2027, with no compelling evidence of mispricing.

1. Market Behavior & Drivers

This prediction market has exhibited a sideways trading pattern, with the probability of a "YES" outcome remaining confined to a narrow 10-point range between 9.0% and 19.0%. Since opening at 12.0%, the price has shown no definitive trend, currently trading at 15.0%. The price action suggests a market in equilibrium, with traders unable to establish a clear directional bias. Key technical levels have formed, with clear support near the 9.0% mark and resistance at the 19.0% ceiling. The market has tested these boundaries but has failed to break out, reinforcing the range-bound behavior.
The price action indicates significant market skepticism despite seemingly positive news. An announcement from the Department of Health and Human Services (HHS) set a reclassification date for February 2026, yet the market price has remained below 20%. This implies that traders believe the HHS announcement is not a final guarantee. The low probability assigned by the market likely stems from uncertainty surrounding the subsequent Pharmacy Compounding Advisory Committee (PCAC) review scheduled for July 2026, which could introduce delays or a reversal of the decision. Total trading volume is very low at 315 contracts, which suggests limited market participation and conviction. This low liquidity means price levels may be influenced by a small number of traders and may not reflect a broad market consensus.
Overall, the chart suggests a deeply skeptical market sentiment. Traders are pricing the probability of reclassification by the resolution date at only 15%, indicating an 85% perceived chance of failure or delay. The persistent low price, despite the HHS news, shows that the market is heavily weighing the risks of regulatory hurdles, particularly the upcoming PCAC review. The tight trading range and low volume reflect this uncertainty, with most participants unwilling to bet strongly on a definitive outcome.
  • HHS announced BPC-157's expected return to Category 1 in February 2026.
  • The FDA's PCAC will review BPC-157 on July 23-24, 2026.
  • Reclassification by November 2026 is highly improbable given procedural steps.
  • A mandatory 60-day public comment period follows the PCAC meeting.
  • BPC-157's limited safety data from rodent studies raises FDA concerns.

Who Wins and Why

Outcome Market Model Why
Before November 64.0% 33.3% The FDA's 60-day public comment period makes reclassification by November highly improbable.
Before 2027 70.0% 66.2% A structured regulatory process is underway following the July 2026 PCAC meeting.

Current Context

BPC-157 was recently placed in FDA Category 2, restricting its availability. In September 2023, BPC-157 was moved to FDA Category 2, which resulted in a ban on its compounding [1]. Gaining Category 1 status is significant because it would permit 503A compounding pharmacies to prepare BPC-157 under a prescription, though this does not equate to full FDA approval [2].
Reclassification to Category 1 is anticipated by early 2026. The Department of Health and Human Services (HHS) has announced a return to Category 1 for BPC-157, effective February 27, 2026 [2]. Further review by the Pharmacy Compounding Advisory Committee (PCAC) for BPC-157 is scheduled for July 23-24, 2026 [3].
Prediction markets indicate high confidence in reclassification by 2027. Current prediction market odds show a 78% likelihood that BPC-157 will be reclassified to Category 1 before January 1, 2027 [4].
Sources (4)
  1. 1BPC-157 and the FDA: Category 2 Explained | RethinkPeptidesrethinkpeptides.com
  2. 2BPC-157 FDA Status & Category 1 Reclassification | Pure Peptide Clinicpurepeptideclinic.com
  3. 3FDA Peptide Meeting July 2026: BPC-157, TB-500 & More | PeptideMarkpeptidemark.com
  4. 4When will the FDA reclassify BPC-157 to Category 1? | Science and Technology Prediction Markets | Solflaresolflare.com

2. Price Chart

Historical Price (Probability)

Outcome probability
Date

3. Significant Price Movements

Notable price changes detected in the chart, along with research into what caused each movement.

Outcome: Before September

📉 May 02, 2026: 14.0pp drop

Price decreased from 71.0% to 57.0%

What happened: The primary driver for the 14.0 percentage point drop in the prediction market on May 02, 2026, was the market's realization of a significant delay in the FDA's formal reclassification of BPC-157, relative to expectations set by an earlier social media catalyst. A February 2026 podcast appearance, deemed a "news social media catalyst," had suggested the reclassification to Category 1 would occur "within weeks" [1][2][3][4]. However, by early May 2026, the formal publication of the updated FDA list remained pending, contradicting this timeline and decreasing the perceived likelihood of reclassification "Before September" [1][3][5]. Social media was a primary driver, as its earlier narrative set expectations that were subsequently unmet, causing the market to reprice the outcome.

Outcome: Before 2027

📈 April 27, 2026: 9.0pp spike

Price increased from 68.0% to 77.0%

What happened: The primary driver of the 9.0 percentage point spike on April 27, 2026, was likely the public dissemination or official announcement that the FDA's Pharmacy Compounding Advisory Committee is scheduled to meet on July 23-24, 2026, to discuss BPC-157's inclusion on the 503A bulk drug substances list [6]. This news signals a concrete step toward potential reclassification consistent with Category 1, directly increasing the probability of the "Before 2027" outcome. No social media activity from key figures or viral narratives were identified as drivers in the provided information. Therefore, social media was irrelevant.

Outcome: Before November

📉 April 21, 2026: 9.0pp drop

Price decreased from 79.0% to 70.0%

What happened: The 9.0 percentage point drop on April 21, 2026, for the "Before November" outcome was primarily driven by the market's re-evaluation of the timing for BPC-157's reclassification to Category 1, following an April 15, 2026, report. While this report stated the FDA "will imminently remove" BPC-157 from Category 2, it also noted that "formal publication was pending" as of March 15 [1][7]. This distinction likely tempered earlier, more optimistic market expectations that the reclassification would be finalized much sooner than "imminent" implied, leading to a downward price correction. Social media activity, particularly earlier, unspecified claims by influential figures like Kennedy Jr. [1][4], likely contributed by setting high expectations that were then recalibrated by the official report's nuances. Consequently, social media was a (b) contributing accelerant, inflaming expectations that were then tempered by traditional news.
Sources (7)
  1. 1agemd.com
  2. 2openloophealth.com
  3. 3bhrcenter.com
  4. 4biopharmadive.com
  5. 5formationmed.com
  6. 6July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026 | FDAfda.gov
  7. 7ssrpinstitute.org

4. Market Data

Contract Snapshot

The market resolves to YES if the FDA announces the reclassification of BPC-157 to Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances List before September 1, 2026. If this specific reclassification does not occur by the deadline, or if BPC-157 is only removed from Category 2 without placement in Category 1, the market resolves to NO. The market will close by August 31, 2026, 11:59 PM EDT, if the event has not occurred.

Available Contracts

Market options and current pricing

Outcome bucket Yes (price) No (price) Last trade probability
Before November $0.71 $0.38 64%
Before 2027 $0.78 $0.30 70%

Market Discussion

Traders are currently split on whether BPC-157 will be reclassified to Category 1 before September (50%), though a reclassification before November (64%) and before 2027 (70%) is seen as more likely. No explicit arguments for "Yes" or "No" have been presented in the discussion. One trader did inquire if a direct movement to the bulks list would satisfy the payout criteria, indicating a potential point of confusion regarding the market's specific resolution rules.

5. Trust Index

Octagon Trust Index Kalshi 77 Good

Order book is critically thin.

Primary risk· Trade quality

How it adds up
Integrity80% of score85Strong
Trade quality20% of score49High Risk

Includes the cost to trade: a $10,000 order can't be filled here because the order book is too thin.

Trust score77Good

Weighted blend with hard caps — a critically weak safety pillar, or a severe trading anomaly, caps the total regardless of the rest. Full methodology · About the Trust Index

Trust profile
Integrity4 screens run · 6 don't apply
Market integrity
84Good

Outcome is hard to influence

No suspicious activity on any screen

Screened clean
Large tradesNo single trade dominates the tape. Clear
Thin-volume movesMoves carried volume Clear
Size patternsNo distribution read Clear
2 screens not run
Outcome control · doesn't apply to this market type
Thin-leg conviction · doesn't apply to this market type
Info fairness
80Good

Structural prior — no screens apply

No suspicious activity on any screen

Screened clean
Information exposureNo concentrated group can know the outcome materially early. Clear
4 screens not run
Move vs. catalyst · doesn't apply to this market type
Longshot repricing · doesn't apply to this market type
Pre-broadcast certainty · doesn't apply to this market type
Cross-venue timing · doesn't apply to this market type
Resolution quality
92Strong

Resolution mechanism is dependable

No suspicious activity on any screen

Resolution rules read: Clear

Liquidity
60Tradeable

Fills fine at modest size

2 contracts · worst first · 1 settled or closed — not scored

Before November34
Very thin · low confidence

Light recent trading — size may not fill near the screen price.

Book spread 124% vs realized 10%
Before 202770
Tradeable · low confidence

Light recent trading — size may not fill near the screen price.

Book spread 98% vs realized 3%
Move quality
73Confirmed

Moves came with real volume

2 contracts · worst first · 1 settled or closed — not scored

Before November63
Mostly confirmed · medium confidence

Volume opposes the move over 24h

Before 202775
Confirmed · medium confidence

Volume confirms the move over 24h

Rule clarity
100Clear

Counts toward Resolution quality, not here

2 contracts · worst first · 1 settled or closed — not scored

Before 2027100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Before November100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Trade quality
49High Risk

Order book is critically thin

Tradable, but expect execution cost beyond small sizes.

Outcome quality 63 (notional-weighted across 2 scored legs)

$100 order: 10.1c slippage (~155% of a 6.5c contract)

$1,000 order: 49.9c slippage (~768% of a 6.5c contract)

$10,000 order: book too thin to fill

1 settled or closed — not scored

Before 202770Market scoreLiquidity70Move quality75Rule clarity100
Why 70
Liquidity
70 · Tradeable · low confidence

Light recent trading — size may not fill near the screen price.

Book spread 98% vs realized 3%
Move quality
75 · Confirmed · medium confidence

Volume confirms the move over 24h

Rule clarity
100 · Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Before November34Market scoreLiquidity34Move quality63Rule clarity100
Why 34
Liquidity
34 · Very thin · low confidence

Light recent trading — size may not fill near the screen price.

Book spread 124% vs realized 10%
Move quality
63 · Mostly confirmed · medium confidence

Volume opposes the move over 24h

Rule clarity
100 · Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear

underwriting_v1.4 · computed Sep 23, 2026

6. What are the key procedural milestones between the July 2026 PCAC meeting and a final FDA reclassification of BPC-157?

PCAC Meeting DateJuly 23-24, 2026 [1][2][3]
Minimum Public Comment Periodat least 60 days [4][5]
Reclassification Probability (before 2027)78% [6][7]
The Pharmacy Compounding Advisory Committee will review BPC-157 in July 2026. This committee (PCAC) is scheduled to convene on July 23-24, 2026, at the FDA White Oak Campus to offer advice on BPC-157 (free base/acetate) for ulcerative colitis under the 503A Bulks List [1][2][3]. While this advice is non-binding, it plays an influential role in the notice-and-comment rulemaking process for the 503A Bulks List [4][8]. This PCAC review follows a February 2026 announcement from the Department of Health and Human Services (HHS), as BPC-157 is currently classified as Category 2, indicating restricted status [9][10][11].
FDA reclassification of BPC-157 involves a multi-stage rulemaking process. Subsequent to the PCAC meeting, the FDA will conduct an internal review of the recommendations [4][5]. The next significant procedural milestone involves the publication of a Notice of Proposed Rulemaking (NPRM), which must include a public comment period lasting at least 60 days [4][5]. The final step in the reclassification process is the publication of the Final Rule [4][5]. Prediction markets currently suggest a 78% probability of BPC-157 reclassification before 2027, and a 68% probability before November 2026 [6][7].
Sources (11)
  1. 1FDA Peptide Meeting July 2026: BPC-157, TB-500 & More | PeptideMarkpeptidemark.com
  2. 2https://public-inspection.federalregister.gov/2026-07361.pdfpublic-inspection.federalregister.gov
  3. 3July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026 | FDAfda.gov
  4. 4https://www.fda.gov/media/174456/downloadfda.gov
  5. 5https://www.fda.gov/media/162174/downloadfda.gov
  6. 6When will the FDA reclassify BPC-157 to Category 1? | Science and Technology Prediction Markets | Solflaresolflare.com
  7. 7When will the FDA reclassify BPC-157 to Category 1? - Kalshikalshi.com
  8. 8https://www.fda.gov/media/126110/downloadfda.gov
  9. 9FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know (Post 1 of 2)thefdalawblog.com
  10. 10BPC-157 Legal Status in 2026: Where Things Stand | RethinkPeptidesrethinkpeptides.com
  11. 11What’s Changing With Peptide Regulation in 2026bscg.org

7. How binding is the February 2026 HHS announcement on the FDA's final decision regarding BPC-157's classification?

HHS BPC-157 Announcement DateFebruary 27, 2026 [1][2][3]
BPC-157 Status Post-HHSRemoved from FDA Category 2, pending PCAC review July 23-24, 2026 [4][5][6]
Event for Prediction Market ResolutionFormal FDA announcement [7][8]
The Department of Health and Human Services (HHS) announced BPC-157's removal from Category 2. On February 27, 2026, HHS announced that BPC-157 was removed from FDA Category 2, which previously prohibited its compounding [1][2][3]. This announcement was made by Secretary RFK Jr. on Joe Rogan Experience #2461, following the withdrawal of nominations [1][2][3][4][5]. BPC-157 is now pending review by the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026 [4][5][6].
The FDA retains final authority for BPC-157 classification, despite the HHS statement. Despite the HHS announcement, the final determination for BPC-157's inclusion on the 503A Bulks List rests with the FDA, which makes these decisions through formal rulemaking [9][10]. The PCAC's recommendations to the FDA are advisory and non-binding [9][10]. Prediction markets are specifically awaiting a formal FDA announcement, rather than the February 2026 HHS statement, to resolve BPC-157's reclassification [7][8].
Sources (10)
  1. 1BPC-157 Legal Status in 2026: Where Things Stand | RethinkPeptidesrethinkpeptides.com
  2. 2BPC-157 FDA Status & Category 1 Reclassification | Pure Peptide Clinicpurepeptideclinic.com
  3. 3BPC-157 FDA Status 2026: What the RFK Reclassification Means for Patients | AgeMDagemd.com
  4. 4https://fda.gov/media/94155/downloadfda.gov
  5. 5July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026 | FDAfda.gov
  6. 6Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDAfda.gov
  7. 7When will the FDA reclassify BPC-157 to Category 1? | Science and Technology Prediction Markets | Solflaresolflare.com
  8. 8When will the FDA reclassify BPC-157 to Category 1?kalshi.com
  9. 9FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List - Frier Levitt FDA Peptide Update 2026: Removal from “Do Not Compound” List and What It Means for Pharmaciesfrierlevitt.com
  10. 10FDA Peptide Meeting July 2026: BPC-157, TB-500 & More | PeptideMarkpeptidemark.com

8. How does the clinical evidence and safety profile for BPC-157 compare to TB-500, another peptide under review by the PCAC in July 2026?

BPC-157 Human Trials3 small trials (one withdrawn) [1]
Tβ4 Phase 1 SafetyDaily doses up to 1260mg for 14 days found safe in Phase 1 Tβ4 trial [2]
Current Regulatory CategoryCategory 2 for BPC-157 and TB-500 [3]
BPC-157's safety data is limited and has raised FDA concerns. The peptide's safety profile largely stems from Croatian rodent studies and three small human trials, which initially reported no adverse effects. However, data from one 2015 human safety trial was subsequently withdrawn [1]. Despite previous findings of no adverse effects in studies concerning cystitis, intraarticular application, and an IV pilot, the FDA expressed concerns about BPC-157 in 2023, citing potential immune response risks, impurities, and insufficient safety data [1].
TB-500's safety is based on studies of its related compound, Tβ4. While TB-500 itself lacks dedicated human trials, research on the related compound thymosin beta-4 (Tβ4) has demonstrated a favorable safety profile. A Phase 1 study involving healthy volunteers who received daily intravenous doses of Tβ4 up to 1260mg for 14 days found the compound to be safe [2]. Additionally, Tβ4 has shown good safety in Phase 2 and 3 trials for various conditions, including dry eye, neurotrophic keratopathy, and ulcers [2].
Both peptides face a key regulatory decision in July 2026. BPC-157 and TB-500 are currently designated as Category 2 substances. Their potential inclusion on the 503A list will be determined by the Pharmacy Compounding Advisory Committee (PCAC) in July 2026 [3]. It is important to note that while inclusion on this list would affect their compounding status, it does not signify full FDA approval [3].
Sources (3)
  1. 1BPC-157: The peptide with big claims and scant evidence | STATstatnews.com
  2. 2Thymosin beta-4 Advanced Drug Monographtrial.medpath.com
  3. 3FDA Sets July 2026 PCAC Hearing for BPC-157, TB-500, MOTS-C, Semax, and More | PeptideKnowpeptideknow.com

9. What specific clinical trial data and public comments on BPC-157 will be available for review by the FDA's PCAC ahead of its July 2026 meeting?

FDA PCAC Review MonthJuly 2026 [1][2][3][4][5][6]
Public Comment Submission DeadlineJuly 9, 2026 [1][2]
Preclinical Evidence BaseOver 100 animal studies [1][4][5][6]
The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review BPC-157 for ulcerative colitis in July 2026. This review, primarily focusing on ulcerative colitis on Day 1 of the meeting, will assess BPC-157's safety, efficacy, and compounding feasibility [1][7][8][2][3][4][5][6]. The committee's determination will influence its potential inclusion on the 503A list [7][4].
BPC-157 shows extensive preclinical data, but limited human clinical trials. While there is an extensive preclinical evidence base, including over 100 animal studies, human clinical data for BPC-157 is considered thin, with no Phase III trials reported [1][4][5][6]. FDA briefing documents related to this review are expected to be released around July 21 [1].
Public input on BPC-157 is due by July 9, 2026. The deadline for submitting public comments for the committee's review is July 9, 2026 [1][2]. These comments should be submitted through docket FDA-2025-N-6895, with the final closing date for the docket being July 22, 2026 [1][2][3].
Sources (8)
  1. 1FDA Peptide Meeting July 2026: BPC-157, TB-500 & More | PeptideMarkpeptidemark.com
  2. 2BPC-157 Public Comment Deadline: July 9 (2026) | The Peptide Catalogthepeptidecatalog.com
  3. 3How to Submit Public Comments on FDA Peptide Compounding (Docket FDA-2025-N-6895) | PeptideKnowpeptideknow.com
  4. 4FDA PCAC Meeting July 2026: 7 Peptides Under Review | PeptideBond.compeptidebond.com
  5. 5FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety | Meto blogmeto.co
  6. 6BPC-157: 544 Studies, FDA PCAC Review Jul 2026 | Kalioskalios.health
  7. 7https://public-inspection.federalregister.gov/2026-07361.pdfpublic-inspection.federalregister.gov
  8. 8July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026 | FDAfda.gov

10. What precedents from past FDA PCAC reviews support the market's high confidence in BPC-157's reclassification to Category 1 before 2027?

BPC-157 Reclassification AnnouncementFebruary 27, 2026, BPC-157 among 14 of 19 Category 2 peptides to return to Category 1 [1][2][3]
BPC-157 PCAC Meeting DateJuly 23, 2026, to evaluate inclusion for 503A Bulks List (ulcerative colitis use) [4][5][6]
Prior Peptide PCAC RejectionsIpamorelin, CJC-1295, Thymosin alpha-1, and AOD-9604 rejected for 503A list in 2024 [7][8][9][10]
No specific FDA PCAC precedents currently support BPC-157's reclassification confidence. While an announcement on February 27, 2026, indicated BPC-157 is among approximately 14 out of 19 Category 2 peptides slated to return to Category 1 [1][2][3], the available information does not include past FDA Pharmacy Compounding Advisory Committee (PCAC) review precedents that specifically support the market's high confidence in BPC-157's reclassification to Category 1 before 2027.
BPC-157's PCAC review is scheduled, but past outcomes suggest caution. The PCAC meeting for BPC-157 is set for July 23, 2026, to evaluate its potential inclusion on the 503A Bulks List, specifically for treating ulcerative colitis [4][5][6]. Although PCAC recommendations are advisory, the final decision rests with the FDA and can be influenced by the current administration [11][12]. In contrast to the optimistic announcement, prior peptide PCAC outcomes in 2024 resulted in the rejection of Ipamorelin, CJC-1295, Thymosin alpha-1, and AOD-9604 from the 503A list [7][8][9][10], outcomes which do not support a high confidence level for BPC-157's reclassification.
Sources (12)
  1. 1BPC-157 FDA Status & Category 1 Reclassification | Pure Peptide Clinicpurepeptideclinic.com
  2. 2BPC-157 and the FDA: Category 2 Explained | RethinkPeptidesrethinkpeptides.com
  3. 3BPC-157 FDA Status 2026: What the RFK Reclassification Means for Patients | AgeMDagemd.com
  4. 4July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026 | FDAfda.gov
  5. 5BPC-157: 544 Studies, FDA PCAC Review Jul 2026 | Kalioskalios.health
  6. 6FDA Sets July 2026 PCAC Hearing for BPC-157, TB-500, MOTS-C, Semax, and More | PeptideKnowpeptideknow.com
  7. 7https://www.fda.gov/media/185642/downloadfda.gov
  8. 8FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list and sets dates for PCAC review - Lexologylexology.com
  9. 9FDA Removes Certain Peptide Bulk Drug Substances From Category 2 Of Interim 503A Bulks List And Sets Dates For PCAC Review - Life Sciences, Biotechnology & Nanotechnology - United Statesdev.mondaq.com
  10. 10LEGAL PEPTIDE COMPOUNDING GUIDE503A & 503B Regulatory Complianceyoonhangkim.com
  11. 11FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances Listorrick.com
  12. 12The July 2026 FDA peptide advisory committee: what's on the agenda. — The Peptide Examinerthepeptideexaminer.com

11. What Could Change the Odds

Key Catalysts

BPC-157 was moved to Category 2 in September 2023, thereby restricting its compounding availability [1][2]. However, a significant announcement from the Department of Health and Human Services (HHS) on February 27, 2026, indicated that 14 out of 19 peptides, including BPC-157, are expected to return to Category 1 status [1][2][3]. This announcement, made via a podcast, signaled a potential shift in regulatory policy for these compounds.
Despite the HHS announcement, formal reclassification remains pending as of April-May 2026, with the process moving through official channels [4][5][6]. An FDA document indicates BPC-157 has been removed from Category 2, and its future status will be evaluated by the Pharmacy Compounding Advisory Committee (PCAC) during a meeting scheduled for July 23-24, 2026 [7][8][9]. The PCAC is set to assess BPC-157 (both free base and acetate forms) for specific medical applications such as ulcerative colitis and wound healing [7]. Market expectations, as reflected by platforms like Kalshi, anticipate a formal FDA announcement on Category 1 placement before various dates extending into 2027 [10].

Key Dates & Catalysts

  • Expiration: April 22, 2026
  • Closes: January 01, 2027
Sources (10)
  1. 1BPC-157 FDA Status & Category 1 Reclassification | Pure Peptide Clinicpurepeptideclinic.com
  2. 2BPC-157 Legal Status in 2026: Where Things Stand | RethinkPeptidesrethinkpeptides.com
  3. 3BPC-157 FDA Status 2026: What the RFK Reclassification Means for Patients | AgeMDagemd.com
  4. 4BPC-157 Legal Status 2026: FDA Compounding Updatepeptidesrated.com
  5. 5Is BPC-157 FDA-approved? Latest News 2026orionpeptides.org
  6. 6BPC-157: 544 Studies, FDA PCAC Review Jul 2026 | Kalioskalios.health
  7. 7July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026 | FDAfda.gov
  8. 8FDA Announces Change in Status of 12 Peptides - SSRP Institutessrpinstitute.org
  9. 9https://fda.gov/media/94155/downloadfda.gov
  10. 10When will the FDA reclassify BPC-157 to Category 1? - Kalshikalshi.com

13. Historical Resolutions

Historical Resolutions: 2 markets in this series

Outcomes: 0 resolved YES, 2 resolved NO

Recent resolutions:

  • KXFDAANNOUNCE-BPC-26MAY01: NO (May 01, 2026)
  • KXFDAANNOUNCE-BPC-26APR15: NO (Apr 15, 2026)